Coya Therapeutics' Q3 net loss narrows

Coya Therapeutics

12/11/2025 13:12

Overview

Coya Therapeutics Q3 net loss narrows to $2.1 mln from $4.0 mln last year

Company reports $3.6 mln collaboration revenue due to IND approval milestone

Coya completes $23 mln public offering, extending cash runway into 2H 2027

Outlook

Company expects to receive $4.2 mln milestone payment upon first patient dosing in ALS trial

Coya plans IND submission for COYA 302 in FTD by Q4 2025

Company anticipates extending cash runway into 2H 2027

Result Drivers

R&D EXPENSES - Increase in R&D expenses due to clinical advancement of COYA 302 in ALS

Research and development (R&D) expenses were $2.9 million for the three months ended September 30, 2025, compared to $2.2 million for the three months ended September 30, 2024

Key Details

Metric
Beat/Miss
Actual
Consensus Estimate
Q3 Net Income
-$2.10 mln


Analyst Coverage

The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 7 "strong buy" or "buy", no "hold" and no "sell" or "strong sell"

The average consensus recommendation for the biotechnology & medical research peer group is "buy"

Wall Street's median 12-month price target for Coya Therapeutics Inc is $15.50, about 61.2% above its November 11 closing price of $6.01

Press Release: ID:nBw44BH06a

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)